8 results
This study is designed to investigate whether it is possible to achieve substantial improvement of HbA1c values in preconceptional suboptimal regulated type 1 diabetes mellitus (which is HbA1c 7.0-7.7%). Primary outcome- Absolute reduction in…
This study is designed to investigate whether it is possible to achieve substantial improvement in HbA1c values using RT-CGMS in women with type 1 diabetes with acceptable but not optimal glycaemic control in preconceptional period (which is HbA1c…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
Objectives: The following trial objectives for adolescent patients (from 12 and up to 18 years of age) with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:* Assess the effect of eculizumab on TMA-Event Free status…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
PRIMARY OBJECTIVES * To evaluate the efficacy of lebrikizumab compared with placebo as measured by theability of patients to achieve lower daily doses of OCS while maintaining control oftheir asthma* To evaluate periostin as a predictive biomarker…
EFFICACY OBJECTIVESThe primary efficacy objective for this study is to evaluate the efficacy of lebrikizumabused as adjunctive therapy with TCS compared with TCS in patients with persistentmoderate to severe AD, as measured by Eczema Area and…
To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16